Novo Nordisk A/S Release: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients With Type 2 Diabetes

SAN FRANCISCO, CA--(Marketwire - June 09, 2008) - Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral anti-diabetic drug (OAD).

MORE ON THIS TOPIC